Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

My new book examines the life, death, and legacies of Ryan White, the Indiana teenager with hemophilia who contracted HIV ...

China has approved its first gene therapy for hemophilia B, an inherited bleeding disorder caused by the deficiency of ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

In this cohort of individuals with hemophilia, the physical activity levels and step count did not significantly differ between severity phenotypes. Evidence Rating Level: 1 (Excellent) Hemophilia is ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

Fitusiran is an anti-thrombin-directed small interfering ribonucleic acid therapeutic that prevents bleeds in patients with hemophilia A or B by reducing antithrombin levels. The efficacy and ...